Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | KDM1A | O60341 | 10/20 | 0.54 |
| ▸ | MAOB | P27338 | 2/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.48 |
| ▸ | TLR2 | O60603 | 1/20 | 0.48 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15540699 | 1.00 | SMN1; SMN2 (0.62) | SMN1; SMN2NPSR1KDM1AMAOBHRH3 | |
| SCHEMBL20554238 | 1.00 | SMN1; SMN2 (0.62) | SMN1; SMN2NPSR1KDM1AMAOBHRH3 | |
| SCHEMBL15540731 | 1.00 | SMN1; SMN2 (0.62) | SMN1; SMN2NPSR1KDM1AMAOBHRH3 | |
| SCHEMBL20554570 | 1.00 | SMN1; SMN2 (0.62) | SMN1; SMN2NPSR1KDM1AMAOBHRH3 | |
| SCHEMBL8334238 | 0.83 | SMN1; SMN2 (0.68) | SMN1; SMN2NPSR1KDM1AMAOBHRH3 | |
| SCHEMBL25695438 | 0.83 | SMN1; SMN2 (0.68) | SMN1; SMN2NPSR1KDM1AMAOBHRH3 | |
| Hydrochloric Acid SCHEMBL28626845 | 0.81 | SMN1; SMN2 (0.66) | SMN1; SMN2NPSR1KDM1AMAOBHRH3 | |
| SCHEMBL12483547 | 0.81 | SMN1; SMN2 (0.70) | SMN1; SMN2NPSR1KDM1AMAOBHRH3 | |
| SCHEMBL15540846 | 0.80 | MTNR1A (0.43) | SMN1; SMN2NPSR1 | |
| SCHEMBL15541812 | 0.80 | MTNR1A (0.43) | SMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2867226-B1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2018-11-14 | — | — | EP | disclosed |
| US-9815819-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2017-11-14 | — | — | US | disclosed |
| US-9815819-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2017-11-14 | — | — | US | disclosed |
| US-20150141455-A1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2015-05-21 | — | — | US | disclosed |
| US-20150141455-A1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2015-05-21 | — | — | US | disclosed |
| EP-2867226-A2 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | Novartis AG (CH) | 2015-05-06 | — | — | EP | disclosed |
| WO-2014002051-A2 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2014-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141455-A1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | C5, C3AR1, C9 | SMN1; SMN2 3532/4885NPSR1 776/4885KDM1A 4705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.